As a leading US company, InVitria specializes in developing and manufacturing recombinant proteins and supplements for use in biomanufacturing and the final formulation of vaccines, biologic medicines, cell therapies, gene therapies, and regenerative medicines. Their products are sustainably designed, utilizing the ExpressTec system, which employs plants as the production host and eliminates animal-derived components from gene to final product. This approach ensures they provide safe and effective alternatives to serum and serum proteins.

Their customers rely on them for consistent, safe, and effective alternatives to serum and serum proteins, which are often limited, variable from loto-to-lot, and introduce unnecessary risks of pathogen contamination. By choosing InVitria's products, you achieve the performance and scalability you need while making sustainable choices.

Contact us to learn how we can support your work in cell and gene therapy, vaccines, biomanufacturing, or final formulation.